Overview

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients, and Safety in Combination With L-dopa

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and efficacy of administration of AFQ056 in combination with L-dopa, in reducing the number of L-dopa related dyskinesias in Parkinson's disease patients.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis

Treatments:

Levodopa